Deanne Miller - Immutep General Counsel, Company Secretary
Executive
Ms. Deanne Miller, LLB, is Chief Operating Officer, General Counsel, Company Secretary of Prima BioMed Ltd. Ms Miller has broad commercial experience having held legal, investment banking, regulatory compliance and tax advisory positions, including, Legal Counsel at RBC Investor Services, Associate Director at Westpac Group, Legal Compliance Manager at Macquarie Group, Regulatory Compliance Analyst at the Australian Securities and Investment Commission, and Tax Advisor at KPMG. She joined Prima as General Counsel and Company Secretary in October 2012. She has a Combined Bachelor of Laws and Bachelor of Commerce, Accounting and Finance from the University of Sydney. She is admitted as a solicitor in NSW and member of the Law Society of NSW. since 2016.
| Age | 40 |
| Tenure | 8 years |
| Phone | 61 2 8315 7003 |
| Web | https://www.immutep.com |
Immutep Management Efficiency
The company has return on total asset (ROA) of (0.2296) % which means that it has lost $0.2296 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.3849) %, meaning that it generated substantial loss on money invested by shareholders. Immutep's management efficiency ratios could be used to measure how well Immutep manages its routine affairs as well as how well it operates its assets and liabilities.The company has accumulated 2.11 M in total debt with debt to equity ratio (D/E) of 0.02, which may suggest the company is not taking enough advantage from borrowing. Immutep Limited has a current ratio of 13.88, suggesting that it is liquid and has the ability to pay its financial obligations in time and when they become due. Debt can assist Immutep until it has trouble settling it off, either with new capital or with free cash flow. So, Immutep's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Immutep Limited sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Immutep to invest in growth at high rates of return. When we think about Immutep's use of debt, we should always consider it together with cash and equity.
Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Jessica Oien | Cidara Therapeutics | N/A | |
| Robert Yang | Elevation Oncology | N/A | |
| Sanuj Ravindran | aTyr Pharma | 44 | |
| Marie Lindholm | Silence Therapeutics PLC | N/A | |
| Sue Naim | Alx Oncology Holdings | N/A | |
| Dawn Benson | CytomX Therapeutics | N/A | |
| Alan Krasner | Crinetics Pharmaceuticals | 53 | |
| Jill Broadfoot | aTyr Pharma | 62 | |
| Curtis MD | Silence Therapeutics PLC | N/A | |
| Theresa Lowry | Zura Bio Limited | 50 | |
| SPHR CCP | Cidara Therapeutics | N/A | |
| Ben JD | Immix Biopharma | N/A | |
| Robin Andrulevich | Sana Biotechnology | 58 | |
| Kiran MBBS | Zura Bio Limited | 51 | |
| Leslie Nangle | aTyr Pharma | N/A | |
| Snehal Patel | Sana Biotechnology | N/A | |
| Peter Villiger | aTyr Pharma | N/A | |
| John Jordan | Viridian Therapeutics | N/A | |
| Yingli Ma | Structure Therapeutics American | 50 | |
| YulyMae DiNapoli | Cytokinetics | N/A | |
| Joanna Goldstein | Cytokinetics | N/A | |
Management Performance
| Return On Equity | -0.38 | |||
| Return On Asset | -0.23 |
Immutep Limited Leadership Team
Elected by the shareholders, the Immutep's board of directors comprises two types of representatives: Immutep inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Immutep. The board's role is to monitor Immutep's management team and ensure that shareholders' interests are well served. Immutep's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Immutep's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Frederic MD, Chief Officer | ||
| Pete Meyers, Non-Executive Director | ||
| Russell Howard, Non-Executive Director | ||
| Indira Naidu, Joint Sec | ||
| Shengfei Fang, F Sec | ||
| Tom Bloomfield, Joint Company Secretary | ||
| Deanne LLB, Gen COO | ||
| Larisa Chisholm, Bus. Devel. and Intellectual Property Manager | ||
| Christian Mueller, Director Affairs | ||
| YueLing Wong, Non-Executive Deputy Chairman of the Board | ||
| Frederic Triebel, Chief Scientific Officer & Chief Medical Officer | ||
| Deanne Miller, General Counsel, Company Secretary | ||
| Sharron Gargosky, Chief Technical Officer | ||
| Grant Chamberlain, Non-Executive Director | ||
| Lucy Turnbull, Non-Executive Chairman of the Board | ||
| Marc Voigt, CEO, CFO, Chief Bus. Officer, Executive Director, Member of Audit and Risk Committee and Member of Remuneration Committee | ||
| Matthew Gregorowski, IR Contact Officer |
Immutep Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Immutep a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.38 | |||
| Return On Asset | -0.23 | |||
| Operating Margin | (7.18) % | |||
| Current Valuation | 142.99 M | |||
| Shares Outstanding | 879.09 M | |||
| Shares Owned By Insiders | 4.61 % | |||
| Shares Owned By Institutions | 24.04 % | |||
| Price To Earning | (2.50) X | |||
| Price To Book | 2.81 X | |||
| Price To Sales | 33.12 X |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Immutep in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Immutep's short interest history, or implied volatility extrapolated from Immutep options trading.
Becoming a Better Investor with Macroaxis
Macroaxis puts the power of mathematics on your side. We analyze your portfolios and positions such as Immutep Limited using complex mathematical models and algorithms, but make them easy to understand. There is no real person involved in your portfolio analysis. We perform a number of calculations to compute absolute and relative portfolio volatility, correlation between your assets, value at risk, expected return as well as over 100 different fundamental and technical indicators.Build Optimal Portfolios
Align your risk with return expectations
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in employment. You can also try the Options Analysis module to analyze and evaluate options and option chains as a potential hedge for your portfolios.
Complementary Tools for Immutep Pink Sheet analysis
When running Immutep's price analysis, check to measure Immutep's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Immutep is operating at the current time. Most of Immutep's value examination focuses on studying past and present price action to predict the probability of Immutep's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Immutep's price. Additionally, you may evaluate how the addition of Immutep to your portfolios can decrease your overall portfolio volatility.
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets |